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Abstract
The use of complementary and alternative medicine (CAM) is gaining popularity in the Western world.
Among the general public, CAM is often perceived to be associated with less stigma, fewer adverse effects,
and may be more affordable. A number of patients utilize CAM for the treatment of depression; however,
as there is limited scientific evidence, the safety profile of these supplements are largely unknown. In this
case, a 42-year-old man developed hypomania approximately 1 week after S-adenosylmethionine (SAMe)
and 5-hydroxytryptophan (5-HTP) therapy was initiated for depression. The combination of SAMe and 5-
HTP can potentially induce hypomanic episodes.
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Background
The use of complementary and alternative medicine
(CAM) is gaining popularity in the Western world.1
Patients may regard prescription antidepressants with
skepticism due to the black box warning associated with
an increased risk of treatment-emergent suicide, which is
not a warning within CAM labeling.2 Preference may
further align with CAM therapies because of the belief
that ‘‘natural is better.’’1 Among the general public, CAM
may be perceived to be associated with less stigma, fewer
adverse effects, and lower cost.
The use of CAM for depression by patients with mental
illness is estimated to range between 16% and 44%.1
Studies have shown that CAM may have comparable
efficacy in relation to traditional pharmacologic therapy.
However, these studies have scarce scientific support due
to limitations in study design and methodology. Often
these studies have a small sample size, heterogeneity of
study design, and methodological issues with randomiza-
tion and compliance.1,3-6 According to the Canadian
Network for Mood and Anxiety Treatments (CANMAT)
2016 guidelines,1 it is recognized that pharmacologic and/
or psychological treatments are preferred over CAM
therapies due to a higher level of evidence with a higher
standard of quality.
Despite this disclaimer, CANMAT guidelines recommend
CAM, such as exercise and St John’s wort, as first-line
monotherapy for the treatment of mild to moderate
major depressive disorder. Exercise, light therapy, yoga,
omega-3, and S-adenosylmethionine (SAMe) are recom-
mended as second-line adjunctive treatment for major
depressive disorder depending on severity of illness.1
Mental Health America is a nonprofit organization focused
on improving mental health treatment. Mental Health
America published a thorough review of CAM, including
data from the Agency for Healthcare Research and
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Quality and the National Center for Complementary and
Alternative Medicine as well as 10 different textbooks on
CAM. In this review,7 SAMe was recommended as first-line
CAM treatment for mild, moderate, or severe depression,
and 5-hydroxytryptophan (5-HTP) was not recommended
due to insufficient data. Another review8 recommends
avoiding CAM as first-line treatment when patients are an
acute danger to themselves or others or are unable to care
for themselves or dependents in their care.
The use of SAMe and 5-HTP is the focus in this case
report. SAMe is a naturally occurring derivative of L-
methionine and acts as a methyl donor in the production
of neurotransmitters, increasing brain levels of serotonin
and epinephrine.9 5-HTP is a precursor to serotonin that
can be extracted from the African plant known as Griffonia
simplicifolia.10 Typical dosing of each supplement is as
follows: SAMe 400 to 1600 mg daily and 5-HTP 150 to 800
mg daily for depression.11,12 Potential adverse effects
associated with these 2 over-the-counter (OTC) supple-
ments include induction of mania, serotonin syndrome,
gastrointestinal distress, agitation, anxiety, insomnia,
sexual dysfunction, tremor, and headache.5,11-13
Case
This case report describes a 42-year-old man who was
admitted for unspecified mood disorder. The patient had
no known medical or psychiatric history. He denied
substance use, which was confirmed with a negative
urine toxicology screen. His spouse brought him to the
comprehensive psychiatric emergency program with a
chief complaint of ‘‘nervous breakdown.’’ Upon assess-
ment, tangential and racing thoughts were present with
expansive and pressured speech accompanied with an
anxious affect. The patient reported having a difficult time
the past 2 weeks because of recent unemployment, which
was stressful because he was the main caregiver of the
family. His spouse described him over the past week as
being hyperactive, impulsive, loquacious, and irrational
with side-to-side ocular movements. Three days prior to
admission, the patient was in the living room, naked,
screaming, ‘‘I’m great,’’ and pounding his chest. He had
not slept for 2 days prior to admission.
The patient’s mother and father visited and agreed with
the spouse, stating that the patient’s behavior was erratic
and believed it was due to the OTC supplements he had
been taking. The parents described the patient’s baseline
behavior as calm and well mannered. The patient
developed symptoms consistent with hypomania approx-
imately 1 week after initiating SAMe and 5-HTP therapy
for depression (the patient reported initiating SAMe and
5-HTP therapy 10 days prior to admission). The patient
was on a regimen of 200 mg of 5-HTP and 400 mg of
SAMe once daily for 3 days, which then increased to twice
daily administration (Table 1).
The OTC supplements were discontinued by the hospital
team upon admission, and the patient was not started on
new medications. The first night of hospitalization, the
patient slept for 30 minutes. On the morning of the
second day of hospitalization, he was seen with the
treatment team for the first time, presenting as energetic
with an anxious affect. He was displaying flight of ideas
and had pressured and tangential speech. That evening,
the subject slept a total of 7 hours. The patient’s sleep
time increased from an average of 3 hours per night prior
to admission. That same day, the patient continued
presenting with rapid speech, but his thoughts were more
coherent and logical. The patient also reported being
‘‘more focused and sharp.’’ The third day of hospitaliza-
tion, the patient continued to be slightly anxious and
tangential; however, he had less racing thoughts and
pressured speech. The patient was provided with psycho-
therapy options to help with depressive symptoms and
discharged that day with improved symptoms.
Discussion
Based upon the clinical presentation, the subject meets
the Diagnostic Statistical Manual of Mental Disorders, 5th
edition,14 criteria for a hypomanic event. He had a distinct
period of increased activity and energy lasting at least 4
consecutive days and which were present most of the day.
During this period of increased energy, the patient was
more talkative than usual, saw an increase in goal-
directed activity, and experienced pressured speech, flight
of ideas, and decreased need for sleep.14 The disturbance
in mood and change in functioning was observable by
TABLE 1: Timeline of over-the-counter administration and
discontinuation
Days of
Therapy Description of Event
Day 1 Initiation of the following complementary
and alternative medicine:
 SAMe 400 mg daily
 5-HTP 200 mg daily
Day 3 Increased dosage:
 SAMe 400 mg twice daily
 5-HTP 200 mg twice daily
Day 11 Last dose of SAMe and 5-HTP were
administered 2 hours prior to admission
Day 12 After discontinuation of SAMe and 5-HTP:
Less rapid speech, less tangential, more
coherent thought processes, decreased
psychomotor agitation, improved sleep
5-HTP¼ 5-hydroxytryptophan; SAM-e¼ S-adenosylmethionine.
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others, in this case, by the patient’s family. Upon review of
the medication reconciliation, the patient did not receive
any new medications that could have induced the
hypomanic event. Per the Naranjo adverse drug reaction
probability scale,15 the combination of SAMe and 5-HTP
was a possible cause of the hypomanic episode (Table 2).
Undiagnosed bipolar disorder, substance-induced hypo-
mania, and treatment-emergent affective switch are all
considered in the differential. A definitive diagnosis is
difficult to determine with 1 short hospitalization as the
patient had never been formally evaluated by a health
care professional prior to this episode.
Concerning treatment-emergent affective switches, it is
currently a controversial area whether antidepressants
should be used in patients with bipolar disorder. Stud-
ies16-18 have shown antidepressants do not accelerate time
to recovery nor have higher recovery rates compared with
mood stabilizers alone. However, it is a known risk that
antidepressants can cause a switch into a manic or
hypomanic state.16-20 A meta-analysis by Ghaemi et al17
showed that long-term antidepressant treatment had a
72% greater risk for inducing a manic episode compared
with a mood stabilizer alone. The patient’s symptoms
preceding CAM onset were mainly depressive, and the
affective switch was induced after initiation. Also note
that treatment-emergent affective switches are not
instantaneous and may take weeks of treatment before
an antidepressant-induced switch occurs.16,20 The combi-
nation and possible synergistic effect of the OTC
medications taken concomitantly may have increased
the risk of a hypomanic episode. There has been evidence
of SAMe inducing a switch (euphoria, hypomania, or
mania) at a rate of 33% in 9 patients. Six of the affective
switches were recognized to occur after intravenous and 5
after oral SAMe administration.9 Additionally, there has
been at least 1 documented case21 of 5-HTP inducing a
manic event within 1 week’s time; however, the patient
had been on multiple contributing agents including
phenelzine and as-needed prednisone.
Pharmacokinetically, the half-lives of SAMe and 5-HTP are
relatively short, ranging from 80 to 100 minutes and 2 to 6
hours, respectively.11,12 Therefore, discontinuation of both
supplements resulted in symptom resolution quickly.
Last, due to these CAM being non–FDA-approved, it is
impossible to verify the exact quantity of active com-
pound present in each product consumed by the patient.13
SAMe is unstable at room temperature, making it
impossible to know precisely how much SAMe was active
in each capsule.12 Therefore, replication of this event
would be difficult because of each supplement conceiv-
ably containing a different amount of active ingredient.
Conclusion
The use of SAMe and 5-HTP carries the possible risk of
inducing symptoms of mania. This risk may be increased
when both products are used together because both are
thought to increase levels of serotonin in the brain.
Patients with bipolar rather than unipolar depression
appear to be at significantly higher risk of switch. This
case emphasizes the importance of involving health care
providers in baseline assessment and the ongoing
monitoring of CAM for mood disorders. Pharmacists
should be prepared to discuss appropriate warnings and
precautions with patients who seek guidance prior to
initiating therapy.
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